INM News & Events

InMed Pharmaceuticals announced the "successful" completion of pharmacokinetic studies in large animal models for its Alzheimer's disease candidate INM-901. "This marks the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program," the company stated.

Reports FY25 revenue $4.9M vs $4.6M last year. The Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. Eric Adams, InMed Chief Executive Officer, commented, "Throughout fiscal 2025, InMed continued to advance its pharmaceutical pipeline, in particular showcasing INM-901's potential as a small-molecule drug candidate that addresses Alzheimer's disease across several interrelated biological pathways rather than relying on a single mechanism. We are encouraged by the growing body of neuroinflammation data with INM-901. Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer's pathology and may operate independently of amyloid or tau. These results, alongside favorable behavioral outcomes in long-term preclinical studies, strengthen our conviction that a multi-pathway therapy like INM-901 can contribute meaningfully to disease modification."

InMed Pharmaceuticals announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares or pre-funded warrants in lieu thereof and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share or pre-funded warrant in lieu thereof and associated short-term preferred investment option in a private placement priced at-the-market under Nasdaq rules. The short-term preferred investment option to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the resale registration statement. H.C. Wainwright is acting as the exclusive placement agent for the offering.

InMed Pharmaceuticals announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer's disease. The study evaluated INM-901 in an ex vivo model of lipopolysaccharide-induced inflammation in animal brain tissue, which is designed to induce a strong expression of pro-inflammatory cytokines IL-6, IL-1beta, IL-2, and KC/Gro and inflammasome marker NLRP3. Key Findings from the Study: INM-901 significantly reduced levels of NLRP3 and IL-1beta, two inflammasome markers increasingly implicated in the pathogenesis of Alzheimer's disease and other neuroinflammatory diseases. INM-901 treatment resulted in a dose-dependent and statistically significant reduction in several key pro-inflammatory markers, including IL-6, IL-1beta, KC/Gro, and IL-2. INM-901 reduced key pro-inflammatory markers, independent of amyloid-beta or tau pathology, signifying potential to treat other dementia-related diseases.